A
Annelie J.E. Vulink
Publications - 16
Citations - 1947
Annelie J.E. Vulink is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 5, co-authored 5 publications receiving 1796 citations.
Papers
More filters
Journal ArticleDOI
Human CD141(+) (BDCA-3)(+) dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens
Sarah L. Jongbloed,Andrew J. Kassianos,Kylie J. McDonald,Georgina J. Clark,Xinsheng Ju,Catherine E. Angel,Chun-Jen J. Chen,P. Rod Dunbar,Robert Wadley,Varinder Jeet,Annelie J.E. Vulink,Derek N.J. Hart,Derek N.J. Hart,Kristen J. Radford +13 more
TL;DR: In this paper, the authors report the first detailed functional analysis of the human CD141+ DC subset, which is found in human lymph nodes, bone marrow, tonsil, and blood, and the latter proved to be the best source of highly purified cells for functional analysis.
Human CD141(+) (BDCA-3)(+) dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens
Sarah L. Jongbloed,Andrew J. Kassianos,Kylie J. McDonald,Georgina J. Clark,Xinsheng Ju,Catherine E. Angel,Chun-Jen J. Chen,P. Rod Dunbar,Robert Wadley,Varinder Jeet,Annelie J.E. Vulink,Derek N.J. Hart,Derek N.J. Hart,Kristen J. Radford +13 more
TL;DR: The data demonstrate a role for CD141+ DCs in the induction of cytotoxic T lymphocyte responses and suggest that they may be the most relevant targets for vaccination against cancers, viruses, and other pathogens.
Journal ArticleDOI
Human CD1c (BDCA-1)+ myeloid dendritic cells secrete IL-10 and display an immuno-regulatory phenotype and function in response to Escherichia coli.
Andrew J. Kassianos,Melinda Y. Hardy,Xinsheng Ju,Dipti Vijayan,Yitian Ding,Annelie J.E. Vulink,Kylie J. McDonald,Sarah L. Jongbloed,Robert Wadley,Christine A. Wells,Derek N.J. Hart,Kristen J. Radford +11 more
TL;DR: Compared to their mouse CD8+ DC counterparts, human CD141+ DCs did not phagocytose or process E. coli‐derived Ag and failed to secrete cytokines in response to E.E. coli.
Book ChapterDOI
Dendritic cells in cancer immunotherapy.
TL;DR: The use of fully activated DCs, loaded with multiple, immunogenic, cancer-specific antigens, administered to patients with minimal residual disease and the manipulation of regulatory mechanisms underlying peripheral tolerance, may be the ingredients for future success.
Journal ArticleDOI
Therapeutic drug monitoring based precision dosing of oral targeted therapies in oncology: a prospective multicentre study.
Stefanie L. Groenland,Ruben A G van Eerden,Kim Westerdijk,M Meertens,Stijn L.W. Koolen,Dirk Jan A.R. Moes,N. de Vries,Hilde Rosing,Hubert Otten,Annelie J.E. Vulink,Ingrid M.E. Desar,Alex L. T. Imholz,Hans Gelderblom,Nielka P. van Erp,Jos H. Beijnen,Ron H.J. Mathijssen,A. D. R. Huitema,Neeltje Steeghs +17 more
TL;DR: In this article , pharmacokinetically guided dose optimization of oral targeted therapies was feasible in clinical practice and reduced the proportion of underexposed patients considerably, compared with historical data, which is the goal of this study.